<- Go Home
NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Market Cap
$3.2B
Volume
1.0M
Cash and Equivalents
$424.2M
EBITDA
-$244.2M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$7.1M
Profit Margin
100.00%
52 Week High
$42.20
52 Week Low
$21.23
Dividend
N/A
Price / Book Value
5.13
Price / Earnings
-12.78
Price / Tangible Book Value
5.14
Enterprise Value
$2.5B
Enterprise Value / EBITDA
-10.41
Operating Income
-$244.4M
Return on Equity
36.81%
Return on Assets
-20.11
Cash and Short Term Investments
$633.9M
Debt
$82.0K
Equity
$631.4M
Revenue
$7.1M
Unlevered FCF
-$51.3M
Sector
Biotechnology
Category
N/A